S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
NYSEAMERICAN:MTNB

Matinas BioPharma - MTNB Stock Forecast, Price & News

$0.66
+0.01 (+1.54%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.65
$0.68
50-Day Range
N/A
52-Week Range
$0.49
$1.16
Volume
281,640 shs
Average Volume
235,460 shs
Market Capitalization
$143.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Matinas BioPharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
354.5% Upside
$3.00 Price Target
Short Interest
Healthy
0.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.50 out of 5 stars

MTNB stock logo

About Matinas BioPharma (NYSEAMERICAN:MTNB) Stock

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter.

MTNB Stock News Headlines

Deadly Fungi Are Infecting More Americans
Matinas BioPharma Announces Chairman Succession Plan
Matinas BioPharma Holdings Inc (6LJ.MU)
Matinas BioPharma: Q2 Earnings Insights
Matinas Biopharma GAAP EPS of -$0.03
Matinas Biopharma Q1 2022 Earnings Preview
See More Headlines
Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter.

MTNB Company Calendar

Last Earnings
11/02/2022
Today
11/30/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:MTNB
CIK
N/A
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+354.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-23,280,000.00
Pretax Margin
-1,131.80%

Debt

Sales & Book Value

Annual Sales
$30,000.00
Book Value
$0.18 per share

Miscellaneous

Free Float
196,913,000
Market Cap
$143.13 million
Optionable
Not Optionable
Beta
2.01

Key Executives

  • Mr. Jerome D. Jabbour J.D. (Age 48)
    Co-Founder, CEO, Pres & Director
    Comp: $795k
  • Dr. Theresa Matkovits Ph.D. (Age 55)
    Chief Devel. Officer
    Comp: $525.52k
  • Dr. James J. Ferguson FACC (Age 67)
    M.D., Chief Medical Officer
    Comp: $586.3k
  • Mr. Keith A. Kucinski CPA (Age 52)
    M.B.A., Chief Financial Officer
  • Dr. Hui Liu M.B.A. (Age 54)
    Ph.D., Chief Technology Officer
  • Dr. Raphael J. Mannino Ph.D. (Age 75)
    Chief Scientific Officer
  • Mr. Frank Calamusa
    Exec. Director and Head of Manufacturing & Supply Chain
  • Mr. Thomas J. Hoover M.B.A. (Age 52)
    Chief Bus. Officer













MTNB Stock - Frequently Asked Questions

Should I buy or sell Matinas BioPharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MTNB shares.
View MTNB analyst ratings
or view top-rated stocks.

What is Matinas BioPharma's stock price forecast for 2023?

2 Wall Street analysts have issued twelve-month price targets for Matinas BioPharma's stock. Their MTNB share price forecasts range from $3.00 to $3.00. On average, they expect the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 354.5% from the stock's current price.
View analysts price targets for MTNB
or view top-rated stocks among Wall Street analysts.

How have MTNB shares performed in 2022?

Matinas BioPharma's stock was trading at $0.9462 at the beginning of the year. Since then, MTNB shares have decreased by 30.2% and is now trading at $0.66.
View the best growth stocks for 2022 here
.

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) announced its quarterly earnings results on Wednesday, November, 2nd. The company reported ($0.03) EPS for the quarter, hitting analysts' consensus estimates of ($0.03). The firm had revenue of $1.06 million for the quarter, compared to analyst estimates of $1.07 million.

What other stocks do shareholders of Matinas BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include KushCo (KSHB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), OrganiGram (OGI), Novan (NOVN), Zosano Pharma (ZSAN) and Aeterna Zentaris (AEZS).

What is Matinas BioPharma's stock symbol?

Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."

Who are Matinas BioPharma's major shareholders?

Matinas BioPharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.89%), BlackRock Inc. (1.97%), Sargent Investment Group LLC (1.94%), Private Advisor Group LLC (0.08%), Platform Technology Partners (0.07%) and Jane Street Group LLC (0.06%). Insiders that own company stock include Adam K Stern, Jerome D Jabbour and Patrick G Lepore.
View institutional ownership trends
.

How do I buy shares of Matinas BioPharma?

Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Matinas BioPharma's stock price today?

One share of MTNB stock can currently be purchased for approximately $0.66.

How much money does Matinas BioPharma make?

Matinas BioPharma (NYSEAMERICAN:MTNB) has a market capitalization of $143.13 million and generates $30,000.00 in revenue each year. The company earns $-23,280,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.

How can I contact Matinas BioPharma?

Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The official website for the company is www.matinasbiopharma.com. The company can be reached via phone at (908) 443-1860 or via email at mtnb@jtcir.com.

This page (NYSEAMERICAN:MTNB) was last updated on 12/1/2022 by MarketBeat.com Staff